Find a Researcher
More than 200 scientific peer-reviewed publications
More than 200 national and international lectures
National Academy of Inventors
Robert Bowser, PhD, is Chief Scientific Officer, the John P. and Betty Van Denburgh Chair for Neuromuscular Disease, and professor and Chair of the Department of Translational Neuroscience at Barrow Neurological Institute.
Dr. Bowser is an internationally recognized leader in ALS research, contributing pioneering efforts to discover and validate biomarkers for ALS and other neurodegenerative diseases. These biomarkers have been instrumental as diagnostic biomarkers of disease and predictors of disease progression. They are also used to evaluate the effectiveness of drug treatments in clinical trials. Additional research in the Bowser Laboratory includes exploring the mechanisms underlying neurodegeneration, developing new technologies for the delivery of drugs into the central nervous system, and defining the spatial expression of genes relative to neuropathology within human tissue samples. Dr. Bowser is the founder of two biotechnology companies and owner of multiple patents around his scientific discoveries.
As deputy chief scientific officer of Barrow Neurological Institute and St. Joseph’s Hospital and Medical Center, Dr. Bowser oversees all research efforts and defines research directions for the institution. Dr. Bowser is also the co-director of a national biorepository of biofluid samples from ALS patients and of a national ALS post-mortem tissue bank. These biofluid and tissue samples linked to clinical information are a critical resource in our search for the cure and used in research efforts throughout the world. Dr. Bowser participates in many clinical research studies and clinical trials to translate research findings from the bench to patients. He has received numerous awards for his work, including the Sheila Essey Award, which is the highest international award for ALS research.
Dr. Bowser obtained his undergraduate degree from Carnegie Mellon University in Pittsburgh and PhD from Yale University in New Haven, Connecticut. He completed fellowship training at the Albert Einstein College of Medicine in New York City and was a faculty member at the University of Pittsburgh School of Medicine from 1994 to 2011, rising through the ranks to full professor. He joined the faculty at Barrow in 2011.
Dr. Bowser’s research efforts are currently funded by many granting agencies, including the National Institutes of Health (NIH), the Department of Defense, Target ALS, and the ALS Association (ALSA).
- Post-doctoral Fellowship, Pathology, Albert Einstein College of Medicine, 1992-1994
- PhD, Yale University, 1992
- BS, Carnegie Mellon University, 1987
- Society for Neuroscience
- American Society for Investigative Pathology
- American Association of Neuropathologists
- New York Academy of Sciences
- ALS Research Group
- International Society for Biological and Environmental Repositories
- American Association for the Advancement of Science
- World Federation of Neurology Research Group on Motor Neuron Diseases
- The Royal Society of Medicine
- Fellow, National Academy of Inventors, 2020
- IBM Big Data and Analytics Hero, 2016
- Sheila Essey Award for ALS Research, 2015
- NEALS NeuroBank Pioneer Award, 2015
- Arizona Innovation Challenge Award, 2015
- John and Betty VenDenburgh Chair of Neuromuscular Disease, 2012
- Scientific Advisory Board, Northeast Amyotrophic Lateral Sclerosis Consortium, 2011
- Guest Editor, International Journal of Molecular Sciences, 2010
- Science Council, Association Francaise contre les Myopathies, 2009 – 2011
- ALS Association “Walk to D’Feet ALS” Service Award, 2008
- University of Pittsburgh Innovator Award, 2008
- University of Pittsburgh Innovator Award, 2006
- Pittsburgh Magazine “40 under 40” Award for young people shaping the region, 2005
- ALS Association Lou Gehrig’s Challenge Award, 2004
- University of Pittsburgh Chancellor’s Distinguished Public Service Award, 2003
- ALS Association Public Service Award, 2002
ALSUntangled #75: Portable neuromodulation stimulator therapy.
Date: 08/2024
Authors: Laurel Officer, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Michael Benatar, Tulio Bertorini, Robert Bowser, Mark Bromberg, Andrew Brown, Olimpia Mihaela Carbunar, Gregory T Carter, Jesse Crayle, Keelie Denson, Eva Feldman, Timothy Fullam, Terry Heiman-Patterson, Carlayne Jackson, Sartaj Jhooty, Danelle Levinson, Xiaoyan Li, Alexandra Linares, Elise Mallon, Javier Mascias Cadavid, Christopher Mcdermott, Tasnim Mushannen, Lyle Ostrow, Ronak Patel, Gary Pattee, Dylan Ratner, Yuyao Sun, John Sladky, Paul Wicks, Richard Bedlack
Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes.
Date: 06/2024
Authors: Stacy R Lindborg, Namita A Goyal, Jonathan Katz, Matthew Burford, Jenny Li, Haggai Kaspi, Natalie Abramov, Bruno Boulanger, James D Berry, Katharine Nicholson, Tahseen Mozaffar, Robert Miller, Liberty Jenkins, Robert H Baloh, Richard Lewis, Nathan P Staff, Margaret Ayo Owegi, Bob Dagher, Netta R Blondheim-Shraga, Yael Gothelf, Yossef S Levy, Ralph Kern, Revital Aricha, Anthony J Windebank, Robert Bowser, Robert H Brown, Merit E Cudkowicz
Misfolded alpha-synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment.
Date: 04/2024
Authors: Richard Smith, Hanna Hovren, Robert Bowser, Nadine Bakkar, Ralph Garruto, Albert Ludolph, John Ravits, Lia Gaertner, Davan Murphy, Russ Lebovitz
Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice
Date: 12/2023
Authors: Michael Benatar, Lyle W. Ostrow, Joseph W. Lewcock, Frank Bennett, Jeremy Shefner, Robert Bowser, Paul Larkin, Lucie Bruijn, Joanne Wuu
Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial
Date: 12/2023
Authors: Robert Bowser, Jiyan An, Lahar Mehta, Junliang Chen, Jamie Timmons, Merit Cudkowicz, Sabrina Paganoni
- English
More than 200 scientific peer-reviewed publications
More than 200 national and international lectures
National Academy of Inventors
Robert Bowser, PhD, is Chief Scientific Officer, the John P. and Betty Van Denburgh Chair for Neuromuscular Disease, and professor and Chair of the Department of Translational Neuroscience at Barrow Neurological Institute.
Dr. Bowser is an internationally recognized leader in ALS research, contributing pioneering efforts to discover and validate biomarkers for ALS and other neurodegenerative diseases. These biomarkers have been instrumental as diagnostic biomarkers of disease and predictors of disease progression. They are also used to evaluate the effectiveness of drug treatments in clinical trials. Additional research in the Bowser Laboratory includes exploring the mechanisms underlying neurodegeneration, developing new technologies for the delivery of drugs into the central nervous system, and defining the spatial expression of genes relative to neuropathology within human tissue samples. Dr. Bowser is the founder of two biotechnology companies and owner of multiple patents around his scientific discoveries.
As deputy chief scientific officer of Barrow Neurological Institute and St. Joseph’s Hospital and Medical Center, Dr. Bowser oversees all research efforts and defines research directions for the institution. Dr. Bowser is also the co-director of a national biorepository of biofluid samples from ALS patients and of a national ALS post-mortem tissue bank. These biofluid and tissue samples linked to clinical information are a critical resource in our search for the cure and used in research efforts throughout the world. Dr. Bowser participates in many clinical research studies and clinical trials to translate research findings from the bench to patients. He has received numerous awards for his work, including the Sheila Essey Award, which is the highest international award for ALS research.
Dr. Bowser obtained his undergraduate degree from Carnegie Mellon University in Pittsburgh and PhD from Yale University in New Haven, Connecticut. He completed fellowship training at the Albert Einstein College of Medicine in New York City and was a faculty member at the University of Pittsburgh School of Medicine from 1994 to 2011, rising through the ranks to full professor. He joined the faculty at Barrow in 2011.
Dr. Bowser’s research efforts are currently funded by many granting agencies, including the National Institutes of Health (NIH), the Department of Defense, Target ALS, and the ALS Association (ALSA).
- Post-doctoral Fellowship, Pathology, Albert Einstein College of Medicine, 1992-1994
- PhD, Yale University, 1992
- BS, Carnegie Mellon University, 1987
- Society for Neuroscience
- American Society for Investigative Pathology
- American Association of Neuropathologists
- New York Academy of Sciences
- ALS Research Group
- International Society for Biological and Environmental Repositories
- American Association for the Advancement of Science
- World Federation of Neurology Research Group on Motor Neuron Diseases
- The Royal Society of Medicine
- Fellow, National Academy of Inventors, 2020
- IBM Big Data and Analytics Hero, 2016
- Sheila Essey Award for ALS Research, 2015
- NEALS NeuroBank Pioneer Award, 2015
- Arizona Innovation Challenge Award, 2015
- John and Betty VenDenburgh Chair of Neuromuscular Disease, 2012
- Scientific Advisory Board, Northeast Amyotrophic Lateral Sclerosis Consortium, 2011
- Guest Editor, International Journal of Molecular Sciences, 2010
- Science Council, Association Francaise contre les Myopathies, 2009 – 2011
- ALS Association “Walk to D’Feet ALS” Service Award, 2008
- University of Pittsburgh Innovator Award, 2008
- University of Pittsburgh Innovator Award, 2006
- Pittsburgh Magazine “40 under 40” Award for young people shaping the region, 2005
- ALS Association Lou Gehrig’s Challenge Award, 2004
- University of Pittsburgh Chancellor’s Distinguished Public Service Award, 2003
- ALS Association Public Service Award, 2002
ALSUntangled #75: Portable neuromodulation stimulator therapy.
Date: 08/2024
Authors: Laurel Officer, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Michael Benatar, Tulio Bertorini, Robert Bowser, Mark Bromberg, Andrew Brown, Olimpia Mihaela Carbunar, Gregory T Carter, Jesse Crayle, Keelie Denson, Eva Feldman, Timothy Fullam, Terry Heiman-Patterson, Carlayne Jackson, Sartaj Jhooty, Danelle Levinson, Xiaoyan Li, Alexandra Linares, Elise Mallon, Javier Mascias Cadavid, Christopher Mcdermott, Tasnim Mushannen, Lyle Ostrow, Ronak Patel, Gary Pattee, Dylan Ratner, Yuyao Sun, John Sladky, Paul Wicks, Richard Bedlack
Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes.
Date: 06/2024
Authors: Stacy R Lindborg, Namita A Goyal, Jonathan Katz, Matthew Burford, Jenny Li, Haggai Kaspi, Natalie Abramov, Bruno Boulanger, James D Berry, Katharine Nicholson, Tahseen Mozaffar, Robert Miller, Liberty Jenkins, Robert H Baloh, Richard Lewis, Nathan P Staff, Margaret Ayo Owegi, Bob Dagher, Netta R Blondheim-Shraga, Yael Gothelf, Yossef S Levy, Ralph Kern, Revital Aricha, Anthony J Windebank, Robert Bowser, Robert H Brown, Merit E Cudkowicz
Misfolded alpha-synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment.
Date: 04/2024
Authors: Richard Smith, Hanna Hovren, Robert Bowser, Nadine Bakkar, Ralph Garruto, Albert Ludolph, John Ravits, Lia Gaertner, Davan Murphy, Russ Lebovitz
Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice
Date: 12/2023
Authors: Michael Benatar, Lyle W. Ostrow, Joseph W. Lewcock, Frank Bennett, Jeremy Shefner, Robert Bowser, Paul Larkin, Lucie Bruijn, Joanne Wuu
Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial
Date: 12/2023
Authors: Robert Bowser, Jiyan An, Lahar Mehta, Junliang Chen, Jamie Timmons, Merit Cudkowicz, Sabrina Paganoni
- English